Gain-of-function and loss-of-function studies further validated that YBX1 regulated glycolysis- and EMT-related gene expressions and was crucial for tumor invasiveness, thus indicating that YBX1 exhibits clinical diagnostic value and is a potential metabolic target for TNBC. This evidence concerns the gene YBX1 and neoplasm.